The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2

Chemotherapy

Volumn 49, Issue 6, 2003, Pages 303-308

  Wang, Erjia ^a   Johnson, William W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemotherapy; Lonafarnib; Multidrug resistance; P glycoprotein

Indexed keywords

CYCLOSPORIN A; LONAFARNIB; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTINEOPLASTIC AGENTS; CELL LINE; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PIPERIDINES; PYRIDINES;

EID: 0345735895     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074531     Document Type: Review

References (44)

1. Ling V: P-glycoprotein: Its role in drug resistance. Am J Med 1995;99:31S-34S.
2. Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas DH: Immunohistochemical analysis of P-glycoprotein expression in breast cancer: Clinical correlations. Ann Clin Lab Sci 1995;25:52-59.
3. Redmond SM, Joncourt F, Buser K, Ziemiecki A, Altermatt HJ, Fey M, Margison G, Cerny T: Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 1991;51:2092-2097.
4. Johnson WW: P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: Modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol 2002;24:501-514.
5. Shapiro AB, Ling V: Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 1995;270:16167-16175.
6. Wang EJ, Casciano CN, Clement RP, Johnson WW: Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependency. Biochim Biophys Acta 2000;1481:63-74.
7. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B: Clinical reversal of multidrug resistance. Stem Cells 1996;14:56-63.
8. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995;34:235-241.
9. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR, et al: Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:4947-4956.
10. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH: A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res 2000; 60:1871-1877
11. Nielsen LL, Shi B, Hajian G, Yaremko B, Lipari P, Ferrari E, Gurnani M, Malkowski M, Chen J, Bishop WR, Liu M: Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res 1999;59:5896-5901.
12. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH: Synergy of the protein farnesyl-transferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001;7:1438-1445.
13. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G: Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002;1587:318-325.
14. Hoover RR, Mahon FX, Melo JV, Daley GQ: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002;100:1068-1071.
15. Shi B, Yaremko, B Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LL: The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000;46:387-393.
16. Wang E-J, Casciano CN, Clement RP, Johnson WW: The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001;61: 7525-7529.
17. Borst P, Kool M, Evers R: Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Semin Cancer Biol 1997; 8:205-213.
18. Konig J, Nies AT, Cui Y, Leier I, Keppler D: Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461: 377-394.
19. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH: Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000;60:5761-5766.
20. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multi-drug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-3547.
21. Zaman GJ, Versantvoort CH, Smit JJ, Eijdems EW, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EG, Baas F, et al: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993;53:1747-1750.
22. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258: 1650-1654.
23. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M: Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 1999;14:123-131.
24. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001;94:492-499.
25. Wang EJ, Casciano CN, Clement RP, Johnson WW: In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 2000;28:522-528.
26. Wang EJ, Casciano CN, Clement RP, Johnson WW: Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity. Arch Biochem Biophys 2000;382:91-98.
27. Wang E-J, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: Evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun 2001;289:580-585.
28. Shapiro AB, Ling V: Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997; 250:130-137.
29. Larrivee B, Averill DA: Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: Reversal of resistance by cyclosporin A and hyperthermia. Biochem Pharmacol 1999; 58:291-302.
30. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929-937.
31. Hatanaka H, Abe Y, Naruke M, Asai S, Miyachi H, Kawakami T, Nagata J, Kamochi J, Kijima H, Yamazaki H, Scanlon KJ, Ueyama Y, Nakamura M: Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme. Anticancer Res 2001;21:879-885.
32. Hinoshita E, Uchiumi T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K, Kuwano M: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 2000;6: 2401-2407.
33. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Hsieh CY, Pu YS: Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. Anticancer Res 2000;20:3221-3225.
34. Itoh Y, Tamai M, Yokogawa K, Nomura M, Moritani S, Suzuki H, Sugiyama Y, Miyamoto K: Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res 2002;22:1649-1653.
35. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, Kuwano M: Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett 1999;456:327-331.
36. Khokhar NZ, She Y, Rusch VW, Sirotnak FM: Experimental therapeutics with a new 10-de-azaaminopterin in human mesothelioma: Further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clin Cancer Res 2001;7:3199-3205.
37. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M, Kuwano M: A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997;57:5475-5479.
38. Komuro Y, Udagawa Y, Susumu N, Aoki D, Kubota T, Nozawa S: Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin. Jpn J Cancer Res 2001;92:1242-1250.
39. O'Brien ML, Vulevic B, Freer S, Boyd J, Shen H, Tew KD: Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 1999;291: 1348-1355.
40. Kirihara Y, Yamamoto W, Toge T, Nishiyama M: Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 1999;14: 551-556.
41. Zhan M, Liu X: Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cis-platin-resistant human lung adenocarcinoma cell line A549DDP. Chin Med J (Engl) 1999; 112:336-339.
42. Manzano RG, Wright KA, Twentyman PR: Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). Clin Cancer Res 1996;2:1321-1326.
43. Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A: Ifosfamide-based drug combinations: Preclinical evaluation of drug interactions and translation into the clinic. Semin Oncol 2000;27(1 suppl 1):8-13.
44. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:Diverse mechanisms of resistance. Blood 2000;96: 1070-1079.